In fiscal 2025, which ended Dec 31, 2025, Denali Therapeutics Inc. reported revenue of $0. It recorded a net loss of $512.5 million. Diluted earnings per share were -$2.97. Across the 6 fiscal years shown, revenue grew from $129.1 million in fiscal 2018 to $330.5 million in fiscal 2023, about 20.7% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
0
|
0
-100.0%
|
331
+214.6%
|
105
+115.9%
|
49
-85.5%
|
336
+1174.9%
|
26
-79.6%
|
129
|
| Research and development |
405
-3.8%
|
419
+5.6%
|
396
-6.5%
|
424
+18.2%
|
359
+35.2%
|
265
+24.8%
|
213
+9.9%
|
193
+35.1%
|
143
|
| Selling, general and administrative |
—
|
137
+29.5%
|
105
+2.0%
|
103
+14.2%
|
90
+14.4%
|
79
+31.1%
|
60
+29.8%
|
46
+43.7%
|
32
|
| Operating income |
-532
+2.9%
|
-555
-14.0%
|
-487
-147.8%
|
-197
+42.3%
|
-341
-15.2%
|
-296
-571.6%
|
63
+129.4%
|
-213
-359.7%
|
-46
|
| Income tax |
—
|
0
+50.0%
|
0
+126.7%
|
0
+42.9%
|
0
+103.7%
|
-1
-169.9%
|
1
+334.5%
|
-0
|
—
|
| Net income |
-314
+37.0%
|
-513
-21.2%
|
-423
-191.1%
|
-145
+55.5%
|
-326
-12.2%
|
-291
-508.5%
|
71
+136.0%
|
-198
-445.3%
|
-36
|
| Basic EPS |
-1.70
+41.4%
|
-2.97
-15.6%
|
-2.57
-142.5%
|
-1.06
+59.2%
|
-2.60
-8.8%
|
-2.39
-467.7%
|
0.65
|
—
|
—
|
| Diluted EPS |
-1.70
+41.4%
|
-2.97
-15.6%
|
-2.57
-142.5%
|
-1.06
+59.2%
|
-2.60
-8.8%
|
-2.39
-479.4%
|
0.63
|
—
|
—
|
| Weighted average shares, basic |
184
+7.7%
|
173
+5.0%
|
164
+19.7%
|
137
+9.4%
|
126
+3.3%
|
122
+11.5%
|
109
|
—
|
—
|
| Weighted average shares, diluted |
184
+7.7%
|
173
+5.0%
|
164
+19.7%
|
137
+9.4%
|
126
+3.3%
|
122
+7.8%
|
113
|
—
|
—
|
| Other measures | |||||||||
| Depreciation and amortization |
13
+26.4%
|
11
+43.5%
|
8
-53.4%
|
17
+61.1%
|
10
+20.8%
|
9
+0.7%
|
9
+6.8%
|
8
+7.8%
|
7
|
| EBITDA |
-519
+3.4%
|
-544
-13.5%
|
-480
-166.5%
|
-180
+45.5%
|
-330
-15.0%
|
-287
-503.0%
|
71
+134.7%
|
-205
-426.7%
|
-39
|
| Margins | |||||||||
| Operating margin |
—
|
—
|
—
|
-59.51%
|
-324.32%
|
-607.83%
|
18.69%
|
-809.97%
|
-35.92%
|
| Profit margin |
—
|
—
|
—
|
-43.94%
|
-310.28%
|
-597.20%
|
21.20%
|
-750.81%
|
-28.07%
|
| EBITDA margin |
—
|
—
|
—
|
-54.45%
|
-314.43%
|
-590.17%
|
21.23%
|
-779.61%
|
-30.18%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DNLI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1714899
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.